Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Teams with Brazilian Partner on HPV Test Evaluation

NEW YORK (GenomeWeb News) – Trovagene today said that it will collaborate with the PIO XII Foundation in Brazil to evaluate the performance of the firm's urine-based molecular assay for HPV types associated with cervical lesions.

The goal of the study is to determine if the test could potentially replace Pap smears as a primary screening tool for cervical cancer risk within Brazil's healthcare system.

The PIO XII Foundation is affiliated with the Barretos Cancer Hospital, which will conduct the study on Trovagene's test. Further tersm of the alliance were not disclosed.

"This study can pave the way to make HPV screening broadly available to medically underserved patients in our region," Adhemar Longatto Filho, from the Laboratory of Medical Investigation at the University of Sao Paulo and principal investigator for the study at Barretos Cancer Hospital, said in a statement. "Our goal is to provide patients with non-invasive testing options to determine their HPV risk factor and significantly improve women's healthcare in Brazil."

Earlier this year San Diego-based Trovagene inked a deal with India's Strand Life Sciences, under which Strand licensed and agreed to validate Trovagene's HPV urine test and high-risk HPV DNA assay.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.